Scholarlink

<p>Colorectal cancer (CRC) is a highly invasive malignant tumor. At present, the combination of surgery with chemotherapy constitutes the predominant strategy in the treatment of CRC. The serious side effects of chemotherapy profoundly impair patients’ quality of life. It is of great importance to develop novel approach to reduce side effects and increase anti-tumor efficacy in CRC treatment. Bortezomib (Btz), a reversible proteasome inhibitor, possessing both chemotherapeutic and immunotherapeutic effects by inducing cell pyroptotic. However, the application of Btz is impeded by their lack of tumor-targeting capability and lipid solubility. To address these restrictions and develop an ideal drug carrier, we performed a biohybrid approach by fusing liposomes with artificial extracellular vesicles engineered from cancer cells to generate hybrid liposomes (HV@Btz) for the targeted delivery of Btz. In contrast to liposomes, HV@Btz possessed higher cellular uptake efficiency and strong cytotoxicity against CT26 cells by inducing cell pyroptotic. Additionally, HV@Btz had superior tumor-targeting ability and prolonged circulation time. HV@Btz significantly suppressed tumor growth and triggered robust anti-tumor immune response with minimum systemic toxicity in both subcutaneous and orthotopic CRC-bearing mice. This study demonstrated that HV@Btz could serve as a scalable approach by inducing cell pyroptotic for the management of colorectal cancer.</p> Graphical abstract <p>Preparation and application of bortezomib (Btz)-loaded hybrid liposome (HV@Btz) for treatment of CRC in mice. This figure was created by Biorender.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bortezomib-loaded hybrid liposome inducing pyroptosis for targeted therapy against colorectal cancer

  • 期刊论文

  • 发表日期：

    2025年4月9日

查看全文
  • Xiaoyong Wen,
  • Zhongkun Zuo,
  • Leping Yang,
  • Xiaoyan Qi,
  • Zuxing Wei,
  • Shu Xu,
  • Jian Li,
  • Xiong Luo,
  • Gunchu Hu,
  • Zhiqiang Liao

摘要

Colorectal cancer (CRC) is a highly invasive malignant tumor. At present, the combination of surgery with chemotherapy constitutes the predominant strategy in the treatment of CRC. The serious side effects of chemotherapy profoundly impair patients’ quality of life. It is of great importance to develop novel approach to reduce side effects and increase anti-tumor efficacy in CRC treatment. Bortezomib (Btz), a reversible proteasome inhibitor, possessing both chemotherapeutic and immunotherapeutic effects by inducing cell pyroptotic. However, the application of Btz is impeded by their lack of tumor-targeting capability and lipid solubility. To address these restrictions and develop an ideal drug carrier, we performed a biohybrid approach by fusing liposomes with artificial extracellular vesicles engineered from cancer cells to generate hybrid liposomes (HV@Btz) for the targeted delivery of Btz. In contrast to liposomes, HV@Btz possessed higher cellular uptake efficiency and strong cytotoxicity against CT26 cells by inducing cell pyroptotic. Additionally, HV@Btz had superior tumor-targeting ability and prolonged circulation time. HV@Btz significantly suppressed tumor growth and triggered robust anti-tumor immune response with minimum systemic toxicity in both subcutaneous and orthotopic CRC-bearing mice. This study demonstrated that HV@Btz could serve as a scalable approach by inducing cell pyroptotic for the management of colorectal cancer.

Graphical abstract

Preparation and application of bortezomib (Btz)-loaded hybrid liposome (HV@Btz) for treatment of CRC in mice. This figure was created by Biorender.